In addition, some necrotic, PI positive, only (4.0%), cells were also observed. Furthermore, cells treated with a clinically relevant concentration (50 nM) of vincristine, a chemotherapeutic agent known to induce apoptosis in several tumor types BAY 1895344 cell line [24], induced similar levels of necrosis (3.6%), but less than half as much apoptosis (1.2% and 7.5% early and late stages of apoptosis, respectively) as EA in A498 cells. Higher concentrations of vincristine were not tested, thus, it is possible that 100 nM vincristine may have induced similar levels of apoptosis to EA. Overall, our results indicated that EA induced cell death in A498 cells, the majority

of which, occurred after 24 h of treatment, and at least part of this cell death was due to apoptosis. Figure 1 Induction of cell death by EA in A498 RCC cells. A498 cells were cells were treated with EA at 50 and 100 nM. Control cells received 0.1% DMSO (vehicle). All conditions were performed in triplicate. Cells were then incubated with additions for 24 or 48 h before measuring viability using the PrestoBlue® assay (A).

A498 cells were treated with 100 nM EA or vehicle for 24 and 45 h durations. Apoptosis was determined by measuring cytoplasmic histone-associated-DNA-fragments using the Cell Death Erastin in vivo detection ELISAPLUS assay kit (B). A498 cells were selleck inhibitor treated with 100 nM EA or with 0.1% DMSO (control) for 24 and 46 h. Cells were then trypsinized, washed with ice cold PBS, and stained with Alexa Fluor® 488 annexin V and PI and analyzed by flow cytometry (C). Analysis of caspase activity

Having established that EA induced apoptosis in A498 cells, the question remained as to whether caspases were involved in EA-induced apoptosis and if so which ones were involved. To determine if EA induced caspase activation in general, active caspases were measured in Progesterone A498 cells, treated as indicated in Figure 2A, by using the FLICA reagent (Fluorochrome Inhibitor of Caspases) which binds covalently to only active caspases and allows active caspase detection by fluorescence. The etoposide, VP16, a chemotherapeutic agent known to induce apoptosis in multiple tumor types and known to activate caspases [25], was used as a positive control in these experiments. Because the effective dose of VP16 is in the micromolar range and since RCC cells are not nearly as sensitive to VP16 and other standard chemotherapeutic agents when compared to EA, higher concentrations of VP16 were used in these experiments over EA. While active caspases were detected in cells treated with 200 μM VP16, active caspases were not detected in cells treated with 100 nM EA (Figure 2A), a concentration of EA reducing cell viability by 70-80%. To confirm that EA did not induce caspase activation, levels of active caspase-3, an executioner caspase, were also determined. Levels of active caspase-3 were examined by Western Blot analysis in A498 cells treated with 200 nM EA or 0.1% DMSO for 48 h.

It should be emphasized that compounds ZKKs induced apoptosis in the K-562 cells derived

from a woman with chronic myeloid leukemia (CML) in blast crisis (Lozzio and Lozzio, 1975; McGahon et al., 1994). The K-562 cells carry the Philadelphia (Ph) chromosome (Lozzio and Lozzio, 1975). The result of this chromosomal translocation is formation of the oncogenic Bcr-Abl fusion gene that is constitutively active. The product of the Bcr-Abl gene is a protein Selleck JPH203 with tyrosine kinase activity. Bcr-Abl-expressing leukemic cells show resistance to apoptosis induced by chemotherapeutic drugs (McGahon et al., 1994), which seems to be related to overexpression of the antiapoptotic protein Bcl-xL (Horita et al., 2000). In general, K562 cells are highly resistant to multiple anticancer agents and easily transform to 17DMAG drug-resistant lines during treatment by novel drugs (McGahon et al., 1994; Bedi et al., 1995; Amarante-Mendes et al., 1998). Concluding remarks Our results suggest that N-substituted selleck screening library pentabromobenzylisothioureas might be promising anticancer agents. The study on anticancer activity of this compound class in solid tumors is in progress, and further investigations are needed to evaluate their clinical potential. Acknowledgment

This study was supported by the Ministry of Science and Higher Education (Poland) grants: PBZ-MIN 014/P05/2004 IMP dehydrogenase and N N209 371439. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References Amarante-Mendes GP, Naekyung KC, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K (1998) Bcr-Abl exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrom C and activation of caspase-3. Blood 91:1700–1705PubMed Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D,

Vala MS, Akhtar AJ, Hilton J, Jones RJ (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148–1158PubMed Carmona A, Gonzalez-Cadavid NF (1978) Comparative effect of a family of substituted thiopseudoureas on protein synthesis by rat liver and Walker carcinoma ribosomes. Chem Biol Interact 22:309–327PubMedCrossRef Castano T, Encinas A, Perez C, Castro A, Campillo NE, Gil C (2008) Design, syntheses, and evaluation of potential inhibitors of nitric oxide synthase. Bioorg Med Chem 16:6193–6206PubMedCrossRef Garvey EP, Oplinger JA, Tanaoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Paith JE, Furfine ES (1994) Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas.